Cholangiocarcinoma (CCA) is a rare and heterogeneous malignant neoplasm with epithelial cell origin of the biliary duct and histologic and biochemical features of cholangiocyte differentiation. The malignant tumor may arise from any portion of the bile duct i.e., from terminal ductules (canals of Hering) to the ampulla of Vater, as well as at the peribiliary glands (intramural and extramural) and sometimes may affect the gall bladder.
Hitherto, surgical treatments are the only potentially curative therapeutic options for all the subtypes of CCA. However, the majority of CCA patients are diagnosed with late-stage disease, and nearly more than one-fourth of patients considered resectable are found to be unresectable during explorative laparotomy.
The Cholangiocarcinoma (CCA) market report also covers emerging drugs, current treatment practices, Cholangiocarcinoma (CCA) market share of the individual therapies, current and forecasted Cholangiocarcinoma (CCA) Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Cholangiocarcinoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Cholangiocarcinoma (CCA) Market Key Facts
The total diagnosed incident population of Cholangiocarcinoma (CCA) in the 7MM ranges 17,622 in 2018. Among all the countries, the estimates show a higher incidence of Cholangiocarcinoma in the United States.
According to the Cholangiocarcinoma Foundation, about 8,000 people in the US are diagnosed with cholangiocarcinoma each year. It can occur at younger ages but is most common in older people, and the average age of diagnosis is 70–75.
As per DelveInsight insights, the incidence rate varied based on type-specific cases and the estimates showed an increasing trend in the Intrahepatic CCA cases, while Extrahepatic CCA showed a decreasing trend or in some are stable cases
In 2018, the incident cases CCA in Germany was found to be 2,656 which as per DelveInsight’s analysts, shall increase by 2030, due to increasing obesity and increase in other related etiological risk factors
As per Delveinsight, Japan had 4,444 incident cases of Cholangiocarcinoma (CCA) in 2018.
Key Benefits of Cholangiocarcinoma (CCA) Market Report
Cholangiocarcinoma market report provides an in-depth analysis of Cholangiocarcinoma (CCA) Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
The Cholangiocarcinoma market report will help in developing business strategies by understanding the Cholangiocarcinoma (CCA) Market trends & developments, key players, and future market competition that will shape and drive the Cholangiocarcinoma (CCA) market in the upcoming years.
The Cholangiocarcinoma market report covers CCA’s current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Cholangiocarcinoma market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Cholangiocarcinoma (CCA) Market
Cholangiocarcinoma (CCA) market size is anticipated to increase during the study period owing to the increasing Incident population of Cholangiocarcinoma (CCA) patients in the 7MM
The Cholangiocarcinoma (CCA) market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Cholangiocarcinoma (CCA) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Cholangiocarcinoma (CCA) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Cholangiocarcinoma (CCA) Epidemiology
The Cholangiocarcinoma (CCA) epidemiology section covers insights about the historical and current Cholangiocarcinoma patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Cholangiocarcinoma (CCA) Drugs Uptake and Key Market Players
The CCA Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cholangiocarcinoma (CCA) market or expected to get launched in the market during the study period. The analysis covers Cholangiocarcinoma market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Cholangiocarcinoma (CCA) Companies:
And many others.
Cholangiocarcinoma (CCA) Therapies Covered in the Report Include:
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Cholangiocarcinoma (CCA) Competitive Intelligence Analysis
4. Cholangiocarcinoma (CCA) Market Overview at a Glance
5. Cholangiocarcinoma (CCA) Disease Background and Overview
6. Cholangiocarcinoma (CCA) Patient Journey
7. Cholangiocarcinoma (CCA) Epidemiology and Patient Population
8. Cholangiocarcinoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Cholangiocarcinoma Unmet Needs
10. Key Endpoints of Cholangiocarcinoma Treatment
11. Cholangiocarcinoma (CCA) Marketed Products
12. Cholangiocarcinoma (CCA) Emerging Therapies
13. Cholangiocarcinoma (CCA) Seven Major Market Analysis
14. Attribute Analysis
15. Cholangiocarcinoma (CCA) Market Outlook (7 major markets)
16. Cholangiocarcinoma (CCA) Access and Reimbursement Overview
17. KOL Views on the Cholangiocarcinoma (CCA) Market.
18. Cholangiocarcinoma Market Drivers
19. Cholangiocarcinoma Market Barriers
21. DelveInsight Capabilities
Cholangiocarcinoma (CCA) Epidemiology Forecast
DelveInsight’s Cholangiocarcinoma (CCA) – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Cholangiocarcinoma (CCA) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Cholangiocarcinoma (CCA) Pipeline Insights
Cholangiocarcinoma (CCA) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Cholangiocarcinoma (CCA) market.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd. 2432
City: Las Vegas
Country: United States